Chapter 30: Clinical trials targeting the kynurenine pathway

Targeting the Broadly Pathogenic Kynurenine Pathway

Volumn , Issue , 2015, Pages 407-417

  Sheen, Melanie ^a   Soliman, Hatem ^b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Clinical trials; IDO inhibitors; Immune escape; Indoleamine 2,3 dioxygenase; Kynurenine pathway; TDO inhibitors; Tryptophan 2,3 dioxygenase

Indexed keywords

EID: 84956981848     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-319-11870-3_30     Document Type: Chapter

References (52)

1. Muller AJ, Prendergast GC. Marrying immunotherapy with chemotherapy: why say IDO? Cancer Res. 2005;65(18):8065-8. doi: 10.1158/0008-5472.can-05-2213.
2. Wainwright DA, Dey M, Chang A, Lesniak MS. Targeting Tregs in malignant brain cancer: overcoming IDO. Front Immunol. 2013;4:116. doi: 10.3389/fimmu.2013.00116.
3. Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing CD25 + CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol. 1999;163(10):5211-8.
4. Wainwright DA, Balyasnikova IV, Chang AL, Ahmed AU, Moon KS, Auffinger B, et al. IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival. Clin Cancer Res. 2012;18(22):6110-21. doi: 10.1158/1078-0432.ccr-12-2130.
5. Witkiewicz A, Williams TK, Cozzitorto J, Durkan B, Showalter SL, Yeo CJ et al. Expression of indoleamine 2,3-dioxygenase in metastatic pancreatic ductal adenocarcinoma recruits regulatory T cells to avoid immune detection. J Am Coll Surg. 2008;206(5):849-54; discussion 54-6. doi: 10.1016/j.jamcollsurg.2007.12.014.
6. Goyne HE, Cannon MJ. Dendritic cell vaccination, immune regulation, and clinical outcomes in ovarian cancer. Front Immunol. 2013;4:382. doi: 10.3389/fimmu.2013.00382.
7. Feder-Mengus C, Wyler S, Hudolin T, Ruszat R, Bubendorf L, Chiarugi A, et al. High expression of indoleamine 2,3-dioxygenase gene in prostate cancer. Eur J Cancer. 2008;44(15):2266-75. doi: 10.1016/j.ejca.2008.05.023.
8. Holmgaard RB, Zamarin D, Munn DH, Wolchok JD, Allison JP. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J Exp Med. 2013;210(7):1389-402. doi: 10.1084/jem.20130066.
9. Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med. 2005;11(3):312-9. doi: 10.1038/nm1196.
10. Balachandran VP, Cavnar MJ, Zeng S, Bamboat ZM, Ocuin LM, Obaid H, et al. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med. 2011;17(9):1094-100. doi: 10.1038/nm.2438.
11. Muller AC, Dairam A, Limson JL, Daya S. Mechanisms by which acyclovir reduces the oxidative neurotoxicity and biosynthesis of quinolinic acid. Life Sci. 2007;80(10):918-25. doi: 10.1016/j.lfs.2006.11.031.
12. Muller AC, Daya S. Acyclovir inhibits rat liver tryptophan-2,3-dioxygenase and induces a concomitant rise in brain serotonin and 5-hydroxyindole acetic acid levels. Metab Brain Dis. 2008;23(3):351-60. doi: 10.1007/s11011-008-9095-4.
13. Muller AC, Maharaj H, Maharaj DS, Daya S. Aciclovir protects against quinolinic-acid- induced oxidative neurotoxicity. J Pharm Pharmacol. 2005;57(7):883-8. doi: 10.1211/0022357056442.
14. Soderlund J, Erhardt S, Kast RE. Acyclovir inhibition of IDO to decrease Tregs as a glioblastoma treatment adjunct. J Neuroinflammation. 2010;7:44. doi: 10.1186/1742-2094-7-44.
15. Jeong YI, Jung ID, Lee JS, Chang JH, Lee CM, et al. Curcumin suppresses the induction of indoleamine 2,3-dioxygenase by blocking the Janus-activated kinase-protein kinase C delta- STAT1 signaling pathway in interferon-gamma-stimulated murine dendritic cells. J Biol Chem. 2009;284(6):3700-8. doi: 10.1074/jbc.M807328200.
16. Cheng CW, Shieh PC, Lin YC, Chen YJ, Lin YH, Kuo DH, et al. Indoleamine 2,3- dioxygenase, an immunomodulatory protein, is suppressed by (-)-epigallocatechin-3-gallate via blocking of gamma-interferon-induced JAK-PKC-delta-STAT1 signaling in human oral cancer cells. J Agric Food Chem. 2010;58(2):887-94. doi: 10.1021/Jf903377e.
17. Schewe C, Schewe T, Wendel A. Strong inhibition of mammalian lipoxygenases by the antiinfl ammatory seleno-organic compound ebselen in the absence of glutathione. Biochem Pharmacol. 1994;48(1):65-74.
18. Terentis AC, Freewan M, Sempertegui Plaza TS, Raftery MJ, Stocker R, Thomas SR. The selenazal drug ebselen potently inhibits indoleamine 2,3-dioxygenase by targeting enzyme cysteine residues. Biochemistry. 2010;49(3):591-600. doi: 10.1021/bi901546e.
19. Dolusic E, Larrieu P, Moineaux L, Stroobant V, Pilotte L, Colau D, et al. Tryptophan 2,3- dioxygenase (TDO) inhibitors. 3-(2-(pyridyl)ethenyl)indoles as potential anticancer immunomodulators. J Med Chem. 2011;54(15):5320-34. doi: 10.1021/jm2006782.
20. Salter M, Hazelwood R, Pogson CI, Iyer R, Madge DJ, Jones HT, et al. The effects of an inhibitor of tryptophan 2,3-dioxygenase and a combined inhibitor of tryptophan 2,3- dioxygenase and 5-HT reuptake in the rat. Neuropharmacology. 1995;34(2):217-27.
21. Pantouris G, Mowat CG. Antitumour agents as inhibitors of tryptophan 2,3-dioxygenase. Biochem Biophys Res Commun. 2014;443(1):28-31. doi: http://dx.doi.org/10.1016/j.bbrc. 2013.11.037.
22. Qian F, Villella J, Wallace PK, Mhawech-Fauceglia P, Tario Jr JD, Andrews C, et al. Efficacy of levo-1-methyl tryptophan and dextro-1-methyl tryptophan in reversing indoleamine-2,3-dioxygenase- mediated arrest of T-cell proliferation in human epithelial ovarian cancer. Cancer Res. 2009;69(13):5498-504. doi: 10.1158/0008-5472.can-08-2106.
23. Hou DY, Muller AJ, Sharma MD, DuHadaway J, Banerjee T, Johnson M, et al. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res. 2007;67(2):792-801. doi: 10.1158/0008-5472. can-06-2925.
24. Li M, Bolduc AR, Hoda MN, Gamble DN, Dolisca SB, Bolduc AK, et al. The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma. J Immunother Cancer. 2014;2:21. doi: 10.1186/2051-1426-2-21.
25. Yuasa HJ, Ball HJ, Austin CJD, Hunt NH. 1-L-methyltryptophan is a more effective inhibitor of vertebrate IDO2 enzymes than 1-D-methyltryptophan. Comp Biochem Physiol B Biochem Mol Biol. 2010;157(1):10-5. doi: 10.1016/j.cbpb.2010.04.006.
26. Lob S, Konigsrainer A, Zieker D, Brucher BLDM, Rammensee HG, Opelz G, et al. IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism. Cancer Immunol Immunother. 2009;58(1):153-7. doi: 10.1007/s00262- 008-0513-6.
27. Metz R, DuHadaway JB, Kamasani U, Laury-Kleintop L, Muller AJ, Prendergast GC. Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Res. 2007;67(15):7082-7. doi: 10.1158/0008-5472.Can-07-1872.
28. Metz R, Rust S, DuHadaway JB, Mautino MR, Munn DH, Vahanian NN, et al. IDO inhibits a tryptophan sufficiency signal that stimulates mTOR A novel IDO effector pathway targeted by D-1-methyl-tryptophan. Oncoimmunology. 2012;1(9):1460-8. doi: 10.4161/Onci.21716.
29. National Cancer Institute (NCI). A phase 1 study of 1-methyl-D-tryptophan in patients with advanced malignancies. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US); 2007 [cited 2014 Sept 15]. Available from: http://clinicaltrials.gov/show/NCT00567931. NLM Identifier: NCT00567931.
30. Soliman HH, Neuger A, Noyes D, Vahanian NN, Link CJ, Munn D et al. A phase I study of 1-methyl-D-tryptophan in patients with advanced malignancies. ASCO Meeting Abstracts. 2012;30(15 suppl):2501.
31. H. Lee Moffitt Cancer Center and Research Institute, National Cancer Institute (NCI). A phase 1/2 study of Ad.p53 DC vaccine in combination with 1-methyl-D-tryptophan in metastatic solid tumors and invasive breast cancer. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US); 2010 [cited 2014 Sept 15]. Available from: http://clinicaltrials. gov/show/NCT01042535 NLM Identifier: NCT01042535.
32. Soliman HH, Minton SE, Ismail-Khan R, Han HS, Janssen W, Vahanian NN et al. A phase 2 study of Ad.p53 DC vaccine in combination with indoximod in metastatic solid tumors. ASCO Meeting Abstracts. 2014;32(15 suppl):TPS3125.
33. Masonic Cancer Center University of Minnesota. A randomized, double-blind phase II study of Sipuleucel-T (Provenge®) followed by indoximod or placebo in the treatment of patients with asymptomatic or minimally symptomatic metastatic castration resistant prostate cancer. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US); 2012 [cited 2014 Sept 15]. Available from: http://clinicaltrials.gov/show/NCT01560923 NLM Identifier:NCT01560923.
34. Soliman HH, Jackson E, Neuger T, Dees CE, Harvey DR, Han H, et al. A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors. Oncotarget. 2014;5(18):8136-46.
35. NewLink Genetics Corporation. A phase I/II study of indoximod in combination with gemcitabine and nab-paclitaxel in patients with metastatic adenocarcinoma of the pancreas. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US); 2014 [cited 2014 Sept 15]. Available from: http://clinicaltrials.gov/show/NCT02077881 NLM Identifier: NCT02077881.
36. NewLink Genetics Corporation. A phase I/II study of the concomitant administration of indoximod plus ipilimumab for adult patients with metastatic melanoma. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US); 2014 [cited 2014 Sept 15].
37. Kennedy E, Rossi GR, Vahanian NN, Link CJ. Phase 1/2 trial of the indoleamine 2,3- dioxygenase pathway (IDO) inhibitor indoximod plus ipilimumab for the treatment of unresectable stage 3 or 4 melanoma. ASCO Meeting Abstracts. 2014;32(15 suppl):TPS9117.
38. Mautino MR, Jaipuri F, Waldo J, Kumar S, Adams J, Van Allen C, Marcinowicz-Flick A, David M, Vahanian N, Link CJ. NLG919, a novel indoleamine-2,3-dioxygenase (IDO)- pathway inhibitor drug candidate for cancer therapy [abstract]. In: Proceedings of the 104th annual meeting of the American Association for Cancer Research [abstract]. 2013 Apr 6-10; Washington, DC. Philadelphia, PA: AACR; Cancer Res 2013;73(8 Suppl):Abstract 491.
39. NewLink Genetics Corporation. A phase I study of NLG-919 for adult patients with recurrent advanced solid tumors. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US); 2014 [cited 2014 Sept 15]. Available from: http://clinicaltrials.gov/show/NCT02048709 NLM Identifier:NCT02048709.
40. Khleif S, Munn D, Nyak-Kapoor A, Mautino MR, Kennedy E, Vahanian NN et al. First-inhuman phase 1 study of the novel indoleamine-2,3-dioxygenase (IDO) inhibitor NLG-919. ASCO Meeting Abstracts. 2014;32(15 suppl):TPS3121.
41. Liu X, Shin N, Koblish HK, Yang G, Wang Q, Wang K, et al. Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. Blood. 2010;115(17):3520-30. doi: 10.1182/blood-2009-09-246124.
42. Koblish HK, Hansbury MJ, Bowman KJ, Yang G, Neilan CL, Haley PJ, et al. Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors. Mol Cancer Ther. 2010;9(2):489-98. doi: 10.1158/1535-7163.mct-09-0628.
43. Incyte Corporation. A phase I, open-label, dose-escalation study to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of INCB024360 in patients with advanced malignancies. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US); 2010 [cited 2014 Sept 15]. Available from: http://clinicaltrials.gov/show/NCT01195311 NLM Identifier: NCT01195311.
44. Beatty GL, O'Dwyer PJ, Clark J, Shi JG, Newton RC, Schaub R et al. Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the oral inhibitor of indoleamine 2,3-dioxygenase (IDO1) INCB024360 in patients (pts) with advanced malignancies. ASCO Meeting Abstracts. 2013;31(15 suppl):3025.
45. National Cancer Institute (NCI). A pilot study of the immunological effects of neo-adjuvant INCB024360 in patients with epithelial ovarian, fallopian tube or primary peritoneal carcinoma. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US); 2014 [cited 2014 Sept 15]. Available from: http://clinicaltrials.gov/show/NCT02042430 NLM Identifier: NCT02042430.
46. Incyte Corporation. A randomized, open-label, phase 2 study of the IDO inhibitor INCB024360 versus tamoxifen for subjects with biochemical-recurrent-only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer following complete remission with firstline chemotherapy. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US); 2012 [cited 2014 Sept 15]. Available from: http://clinicaltrials.gov/show/NCT01685255 NLM Identifier: NCT01685255.
47. H. Lee Moffitt Cancer Center and Research Institute, Incyte Corporation. A phase II study to determine the safety and efficacy of INCB024360 in patients with myelodysplastic syndromes. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US); 2013 [cited 2014 Sept 15]. Available from: http://clinicaltrials.gov/show/NCT01822691 NLM Identifier: NCT01822691.
48. Roswell Park Cancer Institute, National Cancer Institute (NCI). A phase I/IIb study of DEC205mAb-NY-ESO-1 fusion protein (CDX-1401) given with adjuvant Poly-ICLC in combination with INCB024360 for patients in remission with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express NY-ESO-1 or LAGE-1 Antigen. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US); 2014 [cited 2014 Sept 15]. Available from: http://clinicaltrials.gov/show/NCT02166905 NLM Identifier: NCT02166905.
49. Fred Hutchinson Cancer Research Center, National Cancer Institute (NCI), Incyte Corporation, University of Virginia. A phase II pilot trial of an indoleamine 2,3, dioxygenase-1 (IDO1) inhibitor (INCB024360) plus a multipeptide melanoma vaccine (MELITAC 12.1) in patients with advanced melanoma. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US); 2014 [cited 2014 Sept 15]. Available from: http://clinicaltrials.gov/show/NCT01961115 NLM Identifier: NCT01961115.
50. Incyte Corporation, Merck Sharp & Dohme Corporation. A phase 1/2 study exploring the safety, tolerability, and efficacy of MK-3475 in combination with INCB024360 in subjects with selected solid tumors (phase 1) followed by a randomized, double-blind, placebocontrolled study in subjects with advanced NSCLC (Phase 2) In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US); 2014 [cited 2014 Sept 15]. Available from: http://clinicaltrials.gov/show/NCT02178722 NLM Identifier: NCT02178722.
51. Incyte Corporation. A phase 1/2 randomized, blinded, placebo controlled study of ipilimumab in combination with INCB024360 or placebo in subjects with unresectable or metastatic melanoma. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US); 2012 [cited 2014 Sept 15]. Available from: http://clinicaltrials.gov/show/NCT01604889 NLM Identifier:NCT01604889.
52. Gibney GT, Hamid O, Gangadhar TC, Lutzky J, Olszanski AJ, Gajewski T et al. Preliminary results from a phase 1/2 study of INCB024360 combined with ipilimumab (ipi) in patients (pts) with melanoma. ASCO Meeting Abstracts. 2014;32(15 suppl):3010.